BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 17992475)

  • 1. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
    Lee KH; Choi EY; Hyun MS; Jang BI; Kim TN; Lee HJ; Eun JY; Kim HG; Yoon SS; Lee DS; Kim JH; Kim JR
    Clin Exp Metastasis; 2008; 25(1):89-96. PubMed ID: 17992475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer.
    Lee KH; Choi EY; Hyun MS; Jang BI; Kim TN; Kim SW; Song SK; Kim JH; Kim JR
    Korean J Intern Med; 2006 Mar; 21(1):20-7. PubMed ID: 16646560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
    Bauer TW; Fan F; Liu W; Johnson M; Parikh NU; Parry GC; Callahan J; Mazar AP; Gallick GE; Ellis LM
    Ann Surg; 2005 May; 241(5):748-56; discussion 756-8. PubMed ID: 15849510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma.
    Lee KH; Choi EY; Hyun MS; Eun JR; Jang BI; Kim TN; Lee HJ; Lee DS; Yun SS; Kim HJ; Kim JH; Kim JR
    Tumori; 2008; 94(4):523-30. PubMed ID: 18822689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
    Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
    Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trans-resveratrol, a grapevine-derived polyphenol, blocks hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells.
    De Lédinghen V; Monvoisin A; Neaud V; Krisa S; Payrastre B; Bedin C; Desmoulière A; Bioulac-Sage P; Rosenbaum J
    Int J Oncol; 2001 Jul; 19(1):83-8. PubMed ID: 11408926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells.
    Moriyama T; Kataoka H; Hamasuna R; Yoshida E; Sameshima T; Iseda T; Yokogami K; Nakano S; Koono M; Wakisaka S
    Clin Exp Metastasis; 1999; 17(10):873-9. PubMed ID: 11089886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
    Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
    J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasion-Metastasis by Hepatocyte Growth Factor/c-Met Signaling Concomitant with Induction of Urokinase Plasminogen Activator in Human Pancreatic Cancer: Role as Therapeutic Target.
    Lee KH; Hyun MS; Kim JR
    Cancer Res Treat; 2003 Jun; 35(3):207-12. PubMed ID: 26680937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53.
    Liu WT; Jing YY; Yu GF; Chen H; Han ZP; Yu DD; Fan QM; Ye F; Li R; Gao L; Zhao QD; Wu MC; Wei LX
    Cell Cycle; 2016; 15(7):886-94. PubMed ID: 27077227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
    Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
    Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.
    Patel MB; Pothula SP; Xu Z; Lee AK; Goldstein D; Pirola RC; Apte MV; Wilson JS
    Carcinogenesis; 2014 Aug; 35(8):1891-900. PubMed ID: 24876152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines.
    Lee KH; Choi EY; Kim MK; Hyun MS; Jang BI; Kim TN; Kim SW; Song SK; Kim JH; Kim JR
    Exp Mol Med; 2006 Feb; 38(1):27-35. PubMed ID: 16520550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
    Xie Q; Gao CF; Shinomiya N; Sausville E; Hay R; Gustafson M; Shen Y; Wenkert D; Vande Woude GF
    Oncogene; 2005 May; 24(23):3697-707. PubMed ID: 15782129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
    Ried S; Jäger C; Jeffers M; Vande Woude GF; Graeff H; Schmitt M; Lengyel E
    J Biol Chem; 1999 Jun; 274(23):16377-86. PubMed ID: 10347197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.
    Paciucci R; Vilá MR; Adell T; Díaz VM; Torà M; Nakamura T; Real FX
    Am J Pathol; 1998 Jul; 153(1):201-12. PubMed ID: 9665481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-1β-stimulated urokinase plasminogen activator expression through NF-κB in gastric cancer after HGF treatment.
    Lee KH; Choi EY; Koh SA; Kim MK; Jang BI; Kim SW; Kim JR
    Oncol Rep; 2014 May; 31(5):2123-30. PubMed ID: 24626561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration.
    Sisson TH; Nguyen MH; Yu B; Novak ML; Simon RH; Koh TJ
    Blood; 2009 Dec; 114(24):5052-61. PubMed ID: 19812386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells.
    Nishimura K; Matsumiya K; Miura H; Tsujimura A; Nonomura N; Matsumoto K; Nakamura T; Okuyama A
    Int J Androl; 2003 Jun; 26(3):175-9. PubMed ID: 12755996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.